Last reviewed · How we verify
OSE-127
At a glance
| Generic name | OSE-127 |
|---|---|
| Sponsor | OSE Immunotherapeutics |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis (PHASE2)
- Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OSE-127 CI brief — competitive landscape report
- OSE-127 updates RSS · CI watch RSS
- OSE Immunotherapeutics portfolio CI